Please note that following on from information provided to NICE by the company in March 2014, the appraisal of Apixaban for the prevention of venous thromboembolic events in acute medical illness [ID310] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 310 |
| Referral date | 01 January 2010 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | TBC |
| Executive Lead: | TBC |
| Project manager: | TBC |
| Technical Lead: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 20 January 2023 | Discontinued. Please note that following on from information provided to NICE by the company in March 2014, the appraisal of Apixaban for the prevention of venous thromboembolic events in acute medical illness [ID310] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 20 March 2014 |
The Institute has now been informed by the manufacturer that it will no longer be pursuing a licensing application for apixaban in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. |
| 27 January 2012 |
Following on from advice received from the manufacturer, the dates for this appraisal will be confirmed once regulatory approval timelines are established. |
For further information on our processes and methods, please see our CHTE processes and methods manual